Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Neurology

Can You Have CIDP With a Borderline or Normal Nerve Study?

At a Glance

A borderline nerve conduction study can still fit possible CIDP when symptoms follow the typical pattern and the test shows some changes suggesting damage to the nerve’s protective coating. A completely normal, technically adequate study makes typical CIDP unlikely and calls for expert review and evaluation of other causes.

Getting a nerve conduction study (NCS) that is borderline or inconclusive can be incredibly frustrating. If your results are borderline, limited, or do not show every classic feature of demyelination, it is still possible to have Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) [1]. However, a completely normal, technically adequate study makes typical CIDP highly unlikely. In such cases, your doctor will usually need to evaluate you for other conditions that can mimic CIDP symptoms [2].

The Classic Clinical Pattern

Before interpreting nerve tests, doctors first look for the classic clinical pattern of CIDP: progressive or relapsing muscle weakness in both the upper and lower body, sensory loss, and reduced or absent reflexes that develop over a period of at least 8 weeks [3]. If your symptoms fit this pattern but the NCS is borderline, doctors use established diagnostic criteria to determine the next steps.

Understanding “Possible” CIDP

Doctors diagnose the condition using the 2021 EAN/PNS criteria, which categorize the diagnosis as either CIDP or Possible CIDP [4]. To meet the criteria for standard CIDP, a patient generally needs a compatible clinical pattern alongside clear electrodiagnostic (NCS) abnormalities in at least two motor nerves and two sensory nerves [3][4].

“Possible CIDP” is not a label for having symptoms with a completely normal test. Instead, this category is used when a patient’s clinical picture fits, and the nerve study shows some specific demyelinating abnormalities, but not enough to meet the strict thresholds of the full criteria [4].

Building the Case with Supportive Evidence

When an NCS only meets the criteria for Possible CIDP, doctors look for supportive evidence to increase diagnostic certainty. These tests do not independently prove CIDP—as abnormalities can happen in other diseases—but they help build a stronger case when combined with your symptoms and nerve tests [4]:

  • Cerebrospinal fluid (CSF) analysis: A lumbar puncture (spinal tap) to check for elevated protein. This test has procedural risks and is not specific to CIDP alone [4].
  • Nerve imaging: Using an ultrasound or MRI to look for enlarged nerves [4].
  • Objective treatment response: A trial of CIDP immunotherapy (like IVIG or steroids) [4]. Immunotherapy carries real health risks, so a trial should be led by a specialist, use prespecified objective measures (like grip strength or walking speed), and have clear stopping rules. Feeling subjectively better is not enough to justify long-term treatment [5][6].
  • Nerve biopsy: A surgical sample of a nerve. This is rarely used today because it can cause permanent numbness or pain, and it is usually reserved for complex cases where other diseases are strongly suspected [4].

Why Nerve Conduction Studies Can Be Borderline

Nerve conduction studies measure electrical signals in your nerves to look for demyelination (damage to the nerve’s protective myelin sheath). Diagnosing this requires identifying specific patterns, but technical factors can complicate the interpretation [2]:

  • Temperature and Age: Skin temperature can significantly change nerve measurements [7]. If your limbs are cold, nerve signals slow down naturally, which can resemble demyelinating pathology. Results must also be compared against age-appropriate normal values, as baseline nerve function changes as we get older [8].
  • Incomplete Testing or Proximal Disease: Routine tests often focus on the distal nerves (wrists and ankles). Sometimes, CIDP abnormalities are hiding in the proximal segments (nerve roots closer to the spine). Standard distal testing may miss these, requiring more extended testing or specialized techniques to detect them [9][10].
  • Entrapment Sites: Nerves naturally slow down when they pass through tight spaces, like the carpal tunnel in the wrist. Slowing confined only to these compressible sites can be mistakenly interpreted as generalized CIDP [2][9].
  • Axonal Loss: The nerve fiber itself is the axon. Severe damage to the axon causes very low signal amplitudes. Neurophysiologists must carefully account for this, as severe axonal loss can make demyelination criteria uninterpretable or falsely mimic demyelinating patterns [2][11].

Alternative Diagnoses

If your study is normal or borderline, other causes of neuropathy must be considered. Diabetes, hereditary neuropathies (like Charcot-Marie-Tooth disease), entrapment neuropathies, and metabolic disorders can all mimic CIDP-like symptoms and should be evaluated by your care team [2][12].

When to Seek Expert Review

Because interpreting borderline nerve studies is complex, an isolated abnormal number should never be the sole reason to diagnose CIDP or start treatment [2][13].

If your test is borderline but your symptoms are actively progressing, repeating the study later under standardized conditions may be appropriate [14][1]. Expert review by a specialized neuromuscular neurophysiologist is highly recommended for borderline or confusing cases. In one study of patients who were misdiagnosed with CIDP, expert re-evaluation confirmed the initial electrodiagnostic conclusions in only 45% of the studies [2].

🚨 Urgent Safety Warning: If you experience rapidly worsening weakness, repeated falls, sudden inability to walk, trouble swallowing or speaking, or shortness of breath, seek urgent medical care. These symptoms are not typical for chronic CIDP and may indicate a different, acute neurological emergency.

Common questions in this guide

Can CIDP be diagnosed if my nerve conduction study is borderline?
Yes, CIDP can remain possible when symptoms fit the typical pattern and the study shows some specific changes suggesting demyelination, even if the findings do not meet all criteria for standard CIDP. A completely normal, technically adequate study makes typical CIDP much less likely, so doctors usually consider other causes and may seek expert review.
Does a normal nerve conduction study rule out CIDP?
A normal, technically adequate study makes typical CIDP highly unlikely, but the result must be interpreted in light of which nerves and segments were tested. Proximal involvement or incomplete testing can sometimes require extended studies or specialized techniques.
What does possible CIDP mean under the 2021 EAN/PNS criteria?
Possible CIDP means the clinical pattern fits and the nerve study shows some specific changes suggesting demyelination, but the findings do not reach the thresholds for standard CIDP. It is not simply a diagnosis based on symptoms when the nerve study is completely normal.
What tests can clarify a borderline CIDP nerve study?
Doctors may consider cerebrospinal fluid testing, nerve ultrasound or MRI, and sometimes a carefully monitored treatment trial with objective measures. Nerve biopsy is rarely used because it can cause lasting numbness or pain, and none of these supportive tests proves CIDP by itself.
Why can nerve conduction results look borderline in suspected CIDP?
Cold limbs, age-related reference ranges, incomplete testing of proximal nerve segments, slowing at entrapment sites, and severe axonal loss can affect interpretation. A neuromuscular neurophysiologist can review whether the pattern represents generalized nerve-coating damage.
Should I start IVIG if my nerve conduction study is borderline?
A single borderline result should not be the sole reason to start long-term CIDP treatment. If a specialist recommends a treatment trial, it should include objective measures such as grip strength or walking speed, a discussion of risks, and clear stopping rules.
When is weakness with possible CIDP an emergency?
Rapidly worsening weakness, repeated falls, sudden inability to walk, trouble swallowing or speaking, or shortness of breath warrants urgent medical care. These symptoms may signal an acute neurological emergency rather than typical chronic CIDP.

Get notified when new evidence is published on Chronic inflammatory demyelinating polyneuropathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (14)
  1. 1

    Evaluation of the EFNS/PNS diagnostic criteria in a cohort of CIDP patients.

    Athanasopoulos D, Motte J, Grüter T, et al.

    Annals of clinical and translational neurology 2021; (8(5)):1110-1121 doi:10.1002/acn3.51357.

    PMID: 33826247
  2. 2

    Electrodiagnostic errors contribute to chronic inflammatory demyelinating polyneuropathy misdiagnosis.

    Allen JA, Ney J, Lewis RA

    Muscle & nerve 2018; (57(4)):542-549 doi:10.1002/mus.25997.

    PMID: 29053880
  3. 3

    European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision.

    Van den Bergh PYK, van Doorn PA, Hadden RDM, et al.

    European journal of neurology 2021; (28(11)):3556-3583 doi:10.1111/ene.14959.

    PMID: 34327760
  4. 4

    Tips in navigating the diagnostic complexities of chronic inflammatory demyelinating polyradiculoneuropathy.

    Lewis RA, van Doorn PA, Sommer C

    Journal of the neurological sciences 2022; (443()):120478 doi:10.1016/j.jns.2022.120478.

    PMID: 36368137
  5. 5

    Diagnosis of chronic inflammatory demyelinating polyneuropathy.

    Allen JA, Lewis RA

    Muscle & nerve 2022; (66(5)):545-551 doi:10.1002/mus.27708.

    PMID: 36259623
  6. 6

    Challenges in the Early Diagnosis and Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Adults: Current Perspectives.

    van Doorn IN, Eftimov F, Wieske L, et al.

    Therapeutics and clinical risk management 2024; (20()):111-126 doi:10.2147/TCRM.S360249.

    PMID: 38375075
  7. 7

    Cold effect in median nerve conductions in clinical carpal tunnel syndrome with normal nerve conduction studies.

    Say B, Ergün U, Turgal E, Yardımcı İ

    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2019; (61()):102-105 doi:10.1016/j.jocn.2018.10.133.

    PMID: 30538080
  8. 8

    Electrodiagnostic reference data for sensory nerve conduction studies in Saudi Arabia.

    Alanazy MH, Muayqil T, Aldraihem MO, Alkhawajah NM

    Neurosciences (Riyadh, Saudi Arabia) 2020; (25(2)):112-117 doi:10.17712/nsj.2020.2.20190068.

    PMID: 32351248
  9. 9

    Comparison of the diagnostic accuracy of the 2021 EAN/PNS and 2010 EFNS/PNS diagnostic criteria for chronic inflammatory demyelinating polyradiculoneuropathy.

    Doneddu PE, De Lorenzo A, Manganelli F, et al.

    Journal of neurology, neurosurgery, and psychiatry 2022; (93(12)):1239-1246 doi:10.1136/jnnp-2022-329357.

    PMID: 36190959
  10. 10

    The Diagnostic Accuracy of the Second Revision of the European Academy of Neurology/Peripheral Nerve Society Guideline for Diagnosing Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

    van Doorn IN, Baars AE, Wieske L, et al.

    European journal of neurology 2026; (33(8)):e70726 doi:10.1111/ene.70726.

    PMID: 42549490
  11. 11

    Significance of aberrant nerve conduction in hereditary transthyretin amyloidosis.

    Ide T, Yoshikawa M, Suzuyama K, et al.

    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2026; (33(2)):196-204 doi:10.1080/13506129.2026.2613126.

    PMID: 41524533
  12. 12

    Compound muscle action potential duration ratio for differentiation between Charcot-Marie-Tooth disease and CIDP.

    Kitaoji T, Noto YI, Kojima Y, et al.

    Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology 2023; (146()):124-130 doi:10.1016/j.clinph.2022.12.004.

    PMID: 36608530
  13. 13

    Treatment response in patients with clinical and supportive laboratory features of chronic inflammatory demyelinating polyneuropathy without demyelinative findings on nerve conduction studies: A retrospective study.

    Curry P, Herrmann DN, Stanton M, et al.

    Muscle & nerve 2024; (70(5)):1082-1088 doi:10.1002/mus.28198.

    PMID: 38958279
  14. 14

    Evaluation of diagnostic yield of the 2021 European Academy of Neurology/Peripheral Nerve Society diagnostic criteria for CIDP.

    Kanbayashi T, Hokkoku K, Tachiyama K, et al.

    Muscle & nerve 2024; (69(4)):397-402 doi:10.1002/mus.28014.

    PMID: 38038250

This page explains how borderline or normal nerve conduction studies are considered when CIDP is suspected; it is for education and does not replace medical advice. A neurologist or neuromuscular neurophysiologist should interpret your results and guide treatment decisions.